Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) just unveiled an announcement.
Shanghai Fosun Pharmaceutical’s subsidiary Fosun Kairos has received approval from China’s National Medical Products Administration to initiate Phase I/II clinical trials of FKC289 Injection. The investigational therapy will target patients in China with relapsed or refractory primary light chain amyloidosis and relapsed or refractory membranous nephropathy, two severe and hard-to-treat conditions.
FKC289 is a genetically modified CAR-T cell product designed to simultaneously target BCMA and CD19 surface antigens to deplete pathogenic plasma cells and B cells. The green light for clinical testing underscores Fosun Pharma’s push into next-generation cell therapies and, if successful, could strengthen its position in treating plasma cell diseases and B‑cell‑mediated autoimmune disorders, potentially expanding its innovative drug pipeline and long-term growth prospects.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based healthcare group active in pharmaceuticals and biopharmaceuticals, with operations spanning drug research, development and manufacturing. Through subsidiaries such as Fosun Kairos (Shanghai) Biological Technology, the company focuses on innovative therapies, including advanced cell and gene treatments, for complex and underserved diseases.
Average Trading Volume: 2,705,637
Technical Sentiment Signal: Sell
Current Market Cap: HK$75.27B
Learn more about 2196 stock on TipRanks’ Stock Analysis page.